Greg Gillas - SanBio Company Sr Services
| SNBIF Stock | USD 3.85 0.00 0.00% |
Insider
Greg Gillas is Sr Services of SanBio Company Limited
| Phone | 81 3 6264 3481 |
| Web | https://www.sanbio.jp |
SanBio Company Management Efficiency
The company has return on total asset (ROA) of (0.7379) % which means that it has lost $0.7379 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (1.1932) %, meaning that it generated substantial loss on money invested by shareholders. SanBio Company's management efficiency ratios could be used to measure how well SanBio Company manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Jonathan Pachter | Verastem | 66 | |
| Piyush Gupta | Verastem | N/A | |
| Stephen JD | Geron | 74 | |
| Daniel Calkins | Verastem | 36 | |
| Valerie MD | Elevation Oncology | 46 | |
| Sean Flynn | Verastem | 50 | |
| Shengfei Fang | Immutep Ltd ADR | N/A | |
| Mba MBA | Verastem | 70 | |
| Joseph Ferra | Elevation Oncology | 49 | |
| David Dornan | Elevation Oncology | 46 | |
| Ryan Bloomer | Elevation Oncology | N/A | |
| Christian Mueller | Immutep Ltd ADR | N/A | |
| BPHARM RPh | Verastem | 63 | |
| RPh PharmD | Elevation Oncology | 40 | |
| Michelle MD | Verastem | 48 | |
| Robert Weinberg | Verastem | N/A | |
| Wolfgang MD | Rigel Pharmaceuticals | 58 | |
| Erin Cox | Verastem | N/A | |
| Brian Sullivan | Elevation Oncology | N/A | |
Management Performance
| Return On Equity | -1.19 | |||
| Return On Asset | -0.74 |
SanBio Limited Leadership Team
Elected by the shareholders, the SanBio Company's board of directors comprises two types of representatives: SanBio Company inside directors who are chosen from within the company, and outside directors, selected externally and held independent of SanBio. The board's role is to monitor SanBio Company's management team and ensure that shareholders' interests are well served. SanBio Company's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, SanBio Company's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Keita MBA, President, Executive Officer and Representative Director | ||
| Greg Gillas, Sr Services | ||
| Toru Kawanishi, Chairman and Executive Officer | ||
| Michael McGrogan, VP Devel | ||
| Kazumi Sawaguchi, Co Japan | ||
| Andrew Liu, Co Officer | ||
| Yoshihiro Kakutani, Co Admin | ||
| Akihiro MBA, COO VP | ||
| Naoki Tsukahara, Corp Head | ||
| Bijan Nejadnik, Chief Officer |
SanBio Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right otc stock is not an easy task. Is SanBio Company a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.19 | |||
| Return On Asset | -0.74 | |||
| Current Valuation | 306.98 M | |||
| Shares Outstanding | 61.51 M | |||
| Shares Owned By Insiders | 35.76 % | |||
| Shares Owned By Institutions | 4.88 % | |||
| Price To Earning | (31.91) X | |||
| Price To Book | 11.63 X | |||
| Gross Profit | 447 M | |||
| EBITDA | (4.38 B) |
Currently Active Assets on Macroaxis
Other Information on Investing in SanBio OTC Stock
SanBio Company financial ratios help investors to determine whether SanBio OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in SanBio with respect to the benefits of owning SanBio Company security.